281 related articles for article (PubMed ID: 20375091)
21. Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials.
Mannucci E; Monami M; Di Bari M; Lamanna C; Gori F; Gensini GF; Marchionni N
Int J Cardiol; 2010 Aug; 143(2):135-40. PubMed ID: 19328563
[TBL] [Abstract][Full Text] [Related]
22. The rosigliazone meta-analysis: lessons for the future.
Shuster JJ; Schatz DA
Diabetes Care; 2008 Mar; 31(3):e10. PubMed ID: 18308673
[No Abstract] [Full Text] [Related]
23. Straight talk from... Bruce Psaty. Interviewed by Emma Marris.
Psaty B
Nat Med; 2007 Jul; 13(7):767. PubMed ID: 17618256
[No Abstract] [Full Text] [Related]
24. Panel recommends easing restrictions on rosiglitazone despite concerns about cardiovascular safety.
Mitka M
JAMA; 2013 Jul; 310(3):246-7. PubMed ID: 23860970
[No Abstract] [Full Text] [Related]
25. The rosiglitazone decision process at FDA and EMA. What should we learn?
Pouwels KB; van Grootheest K
Int J Risk Saf Med; 2012; 24(2):73-80. PubMed ID: 22751189
[TBL] [Abstract][Full Text] [Related]
26. Faster publication isn't always better.
Fuster V; Farkouh ME
Nat Clin Pract Cardiovasc Med; 2007 Jul; 4(7):345. PubMed ID: 17589426
[No Abstract] [Full Text] [Related]
27. The record on rosiglitazone and the risk of myocardial infarction.
Psaty BM; Furberg CD
N Engl J Med; 2007 Jul; 357(1):67-9. PubMed ID: 17551162
[No Abstract] [Full Text] [Related]
28. FDA puts restrictions on use of controversial diabetes drug.
Mayo Clin Womens Healthsource; 2011 Feb; 15(2):3. PubMed ID: 21200371
[No Abstract] [Full Text] [Related]
29. Critics press FDA to act on evidence of rosiglitazone's cardiac safety issues.
Mitka M
JAMA; 2010 Jun; 303(23):2341-2. PubMed ID: 20551399
[No Abstract] [Full Text] [Related]
30. FDA committee urges tight restrictions on rosiglitazone.
Roehr B
BMJ; 2010 Jul; 341():c3862. PubMed ID: 20639290
[No Abstract] [Full Text] [Related]
31. Regulatory action on rosiglitazone by the U.S. Food and Drug Administration.
Woodcock J; Sharfstein JM; Hamburg M
N Engl J Med; 2010 Oct; 363(16):1489-91. PubMed ID: 20942663
[No Abstract] [Full Text] [Related]
32. [Uncertainly after publications on glitazones. Elevated myocardial infarction risk is not a class effect].
Erdmann E; Scherbaum WA
MMW Fortschr Med; 2007 Dec; 149(49-50):49-50. PubMed ID: 18236983
[No Abstract] [Full Text] [Related]
33. Outlook on diabetes drug less than rosy. Early work suggests that rosiglitazone (Avandia) may not be best for the heart.
Harv Heart Lett; 2007 Aug; 17(12):1-2. PubMed ID: 17717888
[No Abstract] [Full Text] [Related]
34. Rosiglitazone: trials, tribulations and termination.
Krentz AJ
Drugs; 2011 Jan; 71(2):123-30. PubMed ID: 21275442
[No Abstract] [Full Text] [Related]
35. The value equation for rosiglitazone and pioglitazone in older persons.
Zarowitz BJ
Geriatr Nurs; 2008; 29(1):9-11. PubMed ID: 18267172
[No Abstract] [Full Text] [Related]
36. The ethics of pharmaceutical industry gift-giving: the role of a professional association.
Morin K; Morse LJ
Am J Bioeth; 2003; 3(3):54-5. PubMed ID: 14594494
[No Abstract] [Full Text] [Related]
37. Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review.
Wang AT; McCoy CP; Murad MH; Montori VM
BMJ; 2010 Mar; 340():c1344. PubMed ID: 20299696
[TBL] [Abstract][Full Text] [Related]
38. Analytical issues regarding rosiglitazone meta-analysis.
Claggett B; Wei LJ
Arch Intern Med; 2011 Jan; 171(2):179-80; author reply 180. PubMed ID: 21263111
[No Abstract] [Full Text] [Related]
39. Rosiglitazone and cardiovascular disease: an epidemiologist's perspective.
McGuire DK
Diab Vasc Dis Res; 2007 Jun; 4(2):77-9. PubMed ID: 17654438
[No Abstract] [Full Text] [Related]
40. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
Khanderia U; Pop-Busui R; Eagle KA
Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
